The cancer treatment developer has raised $165m in venture capital from investors including pharmaceutical companies Roche and Pfizer.
US-based oncology treatment developer CytomX Therapeutics has filed for an initial public offering sized up to $100m that will provide exits to pharmaceutical firms Roche and Pfizer.
Founded in 2008, CytomX is developing a range of antibody therapeutics based on its Probody technology platform. Its lead product candidate is CX-072, which helps prevent autoimmune attacks against healthy tissue in the body.
CytomX will use the IPO proceeds to support development and Phase 1 clinical trials for CX-072 and an…
